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Abstract
Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging based 3D topographic brain
glucose metabolism patterns from normal controls (NC) and individuals with dementia of Alzheimer’s
type (DAT) are used to train a novel multi-scale ensemble classification model. This ensemble model
outputs a FDG-PET DAT score (FPDS) between 0 and 1 denoting the probability of a subject to be
clinically diagnosed with DAT based on their metabolism profile. A novel 7 group image stratification
scheme is devised that groups images not only based on their associated clinical diagnosis but also on
past and future trajectories of the clinical diagnoses, yielding a more continuous representation of the
different stages of DAT spectrum that mimics a real-world clinical setting. The potential for using FPDS
as a DAT biomarker was validated on a large number of FDG-PET images (N=2984) obtained from the
Alzheimer's Disease Neuroimaging Initiative (ADNI) database taken across the proposed stratification,
and a good classification AUC (area under the curve) of 0.78 was achieved in distinguishing between
images belonging to subjects on a DAT trajectory and those images taken from subjects not progressing
to a DAT diagnosis. Further, the FPDS biomarker achieved state-of-the-art performance on the mild
cognitive impairment (MCI) to DAT conversion prediction task with an AUC of 0.81, 0.80, 0.77 for the
2, 3, 5 years to conversion windows respectively.
1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the presence of AD pathology
(ADP) such as aberrant deposition of amyloid beta (Aβ) proteins, and the appearance of neurofibrillary
tangles of tau proteins. The initial symptom of AD is cognitive impairment notably in the memory domain,
that gradually involves other domains leading to a clinical diagnosis of dementia of Alzheimer’s type (DAT).
Patients with DAT progressively succumb to severe stages of dementia, requiring complete assistance for
daily activities. DAT is the most common form of dementia, affecting 1 in 9 people over the age of 65
years [1] and as many as 1 in 3 people over the age of 85 [2]. As of 2015, there were an estimated 46.8
million dementia afflicted growing to reach 131.5 million in 2050 [3], projecting a very sizeable burden on
healthcare systems and caregivers worldwide. This impending public health crisis due to rising DAT cases
has prompted drug-development efforts to find treatments for AD that can reduce the severity of ADP or
∗Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database
(http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of
ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators
can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
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Table 1: Novel stratification of ADNI images and associated demographic, clinical & biomarker details.
The stratification was based on two criteria, clinical diagnosis of subjects at the time of FDG-PET image
acquisition and their longitudinal clinical progression. Each image is assigned a membership of the form
‘prefixGroup’, where ‘Group’ is the clinical diagnosis at imaging visit, and ‘prefix’ signals past or future
clinical diagnoses. For e.g., an image is designated as pNC if the subject was assigned a NC diagnosis at
that particular imaging visit, but the subject converts to DAT at a future timepoint. The eDAT images are
associated with the diagnosis of DAT, but the subject had received NC or MCI status during previous ADNI
visits (conversion within ADNI window). Whereas, the sDAT images belong to subjects with a consistent
clinical diagnosis of DAT throughout the ADNI study window, hence these individuals have progressed to
DAT prior to their ADNI recruitment.
Clinical
diagnosis
Dementia Group at Clinical N3 Age MMSE CSF
trajectory name imaging progression [images] [Years] [Max. 30] [t-tau/Aβ1-42]
DAT- sNC:stable NC5 NC NC → NC 753 75.44 (5.95) 29.08 (1.17) 0.37 (0.26)
DAT- uNC:unstable NC NC NC → MCI 110 78.93 (4.91) 29.05 (1.13) 0.47 (0.32)
DAT- sMCI:stable MCI MCI NC → MCI or MCI → MCI 881 75.02 (7.77) 27.86 (1.95) 0.55 (0.47)
DAT+ pNC:progressive NC NC NC → MCI → DAT 58 78.20 (4.43) 28.90 (1.29) 0.59 (0.27)
DAT+ pMCI:progressive MCI MCI NC → MCI → DAT or MCI → DAT 486 74.87 (7.12) 26.77 (2.06) 0.88 (0.52)
DAT+ eDAT:early DAT DAT NC → MCI → DAT or MCI → DAT 232 76.59 (6.77) 22.25 (4.51) 0.94 (0.62)
DAT+ sDAT:stable DAT6 DAT DAT → DAT 464 75.80 (7.49) 22.02 (3.64) 1.03 (0.58)
1 NC: normal controls, MCI: mild cognitive impairment, DAT: dementia of Alzheimer’s type
1 MMSE: mini mental state examination, CSF: cerebrospinal fluid, t-tau: total tau, Aβ1-42: beta amyloid 1-42
2 DAT+: On DAT trajectory, i.e., at some point in time, these subjects will be clinically diagnosed as DAT
2 DAT-: not on the DAT trajectory and will not get a DAT diagnosis in the ADNI window
3 A total of 2984 FDG-PET images were taken from 1298 subjects
3 Number of subjects corresponding to images in each of the groups:
3 sNC (360), uNC (52), sMCI (431), pNC (18), pMCI (205), eDAT (133), sDAT (238)
3 Number of subjects with images across multiple groups:
3 uNC & sMCI (18), pNC & pMCI (7), pNC & eDAT (6), pMCI & eDAT (110), pNC & pMCI & eDAT (2)
4 The mean (standard deviation) age, MMSE score and CSF measure values within each group are given
4 CSF measures were only available for a subset of images in each of the groups:
4 sNC (384), uNC (48), sMCI (470), pNC (24), pMCI (205), eDAT (66), sDAT (230)
5 baseline sNC: N=360, Age: 73.81 (6.07), MMSE: 29.05 (1.22), CSF: 0.36 (0.25)
5 follow-up sNC: N=393, Age: 76.93 (5.44), MMSE: 29.11 (1.11), CSF: 0.39 (0.28)
6 baseline sDAT: N=238, Age: 74.93 (7.87), MMSE: 23.22 (2.13), CSF: 1.02 (0.58)
6 follow-up sDAT: N=226, Age: 76.71 (6.97), MMSE: 20.76 (4.40), CSF: 1.06 (0.58)
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remove it altogether [4, 5]. However, the success of such treatments ultimately depends on the ability to
diagnose DAT as early as possible before irreversible brain damage occurs. Therefore, in recent years there
has been a considerable push towards developing robust biomarkers useful for diagnosing DAT in clinical
practice [6].
Fluorodeoxyglucose positron emission tomography (FDG-PET) is a minimally invasive neuroimaging
technique to quantify the glucose metabolism in the brain which indirectly measures the underlying neuronal
activity [7]. As metabolic disruptions are hypothesized to precede the appearance of cognitive symptoms
in AD [8], FDG-PET imaging presents itself as an attractive tool for investigating the metabolism changes
triggered by ADP across the entire DAT spectrum, ranging from the presymptomatic phase to the mild
cognitive impairment (MCI) stage followed by dementia. Our aim in this work is to develop an automatic
method that can aid in the interpretation of the 3D topographic metabolism patterns encoded in FDG-PET
images for the purpose of DAT diagnosis. To this end, we devised a supervised machine learning framework
that takes as input a FDG-PET image of subject and outputs a continuous value between 0 and 1 termed
as the FDG-PET DAT score (FPDS), which indicates the probability of the subject’s metabolism profile to
be belonging to the DAT trajectory, i.e., how likely is the subject to be clinically diagnosed with DAT.
One of the main contributions of our work is the introduction of a novel approach for stratifying the
imaging data used in the development and validation of the proposed FPDS methodology. Most commonly,
imaging biomarker studies employ a 3 group stratification, where the clinical diagnostic labels of NC, MCI and
DAT assigned at the time of image acquisition are directly used for grouping the imaging data [9]. In contrast,
here we present a stratification scheme that groups images based not only on their associated clinical diagnosis
but also on past and future clinical diagnoses. Our novel stratification is able to more faithfully represent the
different diagnostic trajectories observed in a real-world clinical setting when compared to the stratification
depending only on the diagnosis at a single timepoint. For instance, based on our stratification, we can
distinguish among NC images that stay NC (stable NC, sNC) from those that convert to MCI (unstable NC,
uNC), and from those that convert to DAT (progressive NC, pNC). A similar delineation is also induced
among the MCI and DAT images using our stratification scheme. An important contribution in this paper
is the design of a novel multi-scale ensemble classification model for the proposed FPDS computation. The
ensemble model consists of several individual classifiers trained on features extracted from the FDG-PET
image at multiple scales. The probability predictions from each of these individual classifiers regarding the
association of the given FDG-PET image with a DAT trajectory are fused together to obtain a more robust
final FPDS prediction. Another noteworthy contribution of our work is the exhaustive and comprehensive
statistical evaluation approach used to validate the FPDS predictions. First, the training model fit was
evaluated and then a pseudo-independent test sample consisting of follow-up images corresponding to the
baseline training data was used to obtain a more accurate estimate of the ensemble modelâĂŹs generalization
error. Finally, the predictive performance of the FPDS biomarker was evaluated on a large completely
independent validation set of images taken from different stages of the DAT spectrum demonstrating a
strong generalization potential of the reported results. To the best of our knowledge, ours is the largest
FDG-PET based imaging biomarker study reported till date.
2 Methods
2.1 Study participants
Data used in the preparation of this article was obtained from the ADNI database (adni.loni.usc.edu).
The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers,
and clinical and neuropsychological assessment can be combined to measure the progression of MCI and
early AlzheimerâĂŹs disease. Till date, ADNI has involved 1887 subjects and assessed over one or more
visits. Clinical diagnosis received by these subjects, can be broadly categorized among one of NC, MCI and
DAT. Detailed description of the ADNI recruitment procedure, image acquisition protocols and diagnostic
criteria can be found at www.adni-info.org.
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2.2 Novel database stratification
We devised a novel stratification scheme to distinguish within the NC, MCI and DAT groups based on past
and future clinical diagnosis received by the individual. Each of these three groups were further divided
into subgroups based on the diagnoses received during their follow-up. The subgroups are named according
to the convention ‘prefixGroup’, where ‘Group’ is the clinical diagnosis obtained during the imaging visit,
and ‘prefix’ signifies the past or the future clinical diagnoses of the same individual. Images associated
with clinical diagnosis of NC, and a consistent diagnoses of NC during the entire ADNI study period are
termed as the stable NC (sNC) group. Images associated with clinical diagnosis of NC, but convert to MCI
in the future visits are termed as unstable NC (uNC). Images associated with a clinical diagnosis of NC
and convert to DAT in their future visits are termed as progressive NC (pNC). Similarly, images associated
with MCI are subgrouped as stable MCI (sMCI) and progressive MCI (pMCI) based on persistent MCI
diagnosis and conversion to DAT diagnosis respectively in their subsequent followup. Images with a clinical
diagnosis of DAT who joined ADNI at the DAT stage, i.e., they converted to clinical diagnosis of DAT prior
to ADNI recruitment, and remained DAT for the future ADNI visits are termed as stable DAT (sDAT).
Images with a clinical diagnosis of DAT, with the recent past ADNI clinical diagnosis of either NC or MCI,
i.e., they converted to DAT within the ADNI visits are termed as early DAT (eDAT). Note that a past or
future clinical diagnosis visit may or may not include neuroimaging, but the past or future clinical diagnosis
enables an enriched staging of each image given the evolution of clinical diagnosis.
The proposed stratification provides key advantage, offers subgroups namely pNC, pMCI, eDAT and
sDAT, that represent various stages of DAT trajectory. The pNC subgroup is the earliest, the sDAT subgroup
is the most advanced and the pMCI and eDAT subgroups are in-between these extremes along the DAT
spectrum. These are denoted as the DAT+ class of images indicating their trajectory towards DAT. The
subjects in the sNC, uNC and sMCI subgroups do not include a followup clinical diagnosis of DAT during
the ADNI window; so although there is the possibility that post-ADNI these could progress to a clinical
diagnosis of DAT, for the purposes of analysis in this paper, these subgroups are considered to not be on the
DAT+ trajectory, hence denoted as DAT-.
2.3 MRI processing
Pre-processing of the 3D structural MPRAGE T1-weighted MRI images from ADNI included standard
intensity normalization to remove image geometry distortions arising from gradient non-linearity, B1 cali-
brations to correct for image intensity non-uniformities and N3 histogram peak sharpening (http://adni.
loni.usc.edu/methods/mri-analysis/mri-pre-processing). The pre-processed images were segmented
into the gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) tissue regions [10] using the
Freesurfer software package (https://surfer.nmr.mgh.harvard.edu). A rigorous quality control procedure
was employed to manually identify and correct any errors in the automated tissue segmentations following
Freesurfer’s troubleshooting guidelines. Subsequently, the GM tissue region was parcellated into 85 different
anatomical ROIs using Freesurfer’s cortical [11] and subcortical [12] labeling pipelines.
2.4 FDG-PET processing
The ADNI FDG-PET images used in this study were pre-processed using a series of steps to mitigate
inter-scanner variability and obtain FDG-PET data with a uniform spatial resolution and intensity range
for further analysis (http://adni.loni.usc.edu/methods/PET-analysis/pre-processing). Briefly, the
original raw FDG-PET frames were co-registered and averaged to obtain a single FDG-PET image, which
was then mapped from its native space to a standard 160 × 160 × 96 image grid with 1.5 × 1.5 × 1.5 mm3
voxels. After standardizing the spatial resolution and orientation, the intensity range of the FDG-PET image
was normalized such that average intensity of all the foreground voxels in the image was exactly equal to one.
The intensity normalized images were then filtered using scanner-specific filter functions to obtain FDG-PET
data at a uniform smoothing level of isotropic 8 mm full width at half maximum (FWHM) Gaussian kernel.
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2.5 Multi-scale patch-wise FDG-PET SUVR features
In order to better localize the average regional glucose metabolism signal, each of the 85 GM ROIs obtained
using Freesurfer were further subdivided into smaller volumetric sub-regions or patches. Our previously pro-
posed adaptive surface patch generation method [13], which is based on k-means clustering, was applied to the
3D image domain to obtain a patch-wise parcellation of the GM ROIs. Instead of subdividing each GM ROI
into a fixed number of patches, the number of patches per ROI were adaptively determined using the patch
size parameter (m), denoting the number of voxels in each patch. This achieves a patch density (patches in
ROI/voxels in ROI) that is uniform (≈ 1m ) throughout the image domain, which is desirable, as it leads to
a compact yet rich description of the entire GM tissue region. The scale-space theory framework [14] argues
for storing the signal at multiple scales in the absence of a-priori knowledge regarding the appropriate scale
at which to analyze the signal. Motivated by this scale-space idea, we generated 16 different levels of patch-
wise parcellations, m = {100, 150, 200, 250, 300, 350, 400, 450, 500, 1000, 1500, 2000, 3000, 4000, 5000, 10000}
to obtain a fine to coarse multi-scale representation of the GM region for capturing the regional glucose
metabolism signals at different scales. We note that the patch-wise parcellations were initially generated on
the standard MNI ICBM 152 non-linear average T1 template [15] (http://nist.mni.mcgill.ca/?p=858)
and then were propagated to each of the target MRI images in our dataset using the large deformation diffeo-
morphic metric mapping (LDDMM) non-rigid registration [16]. This template-based parcellation approach
ensures a one-to-one correspondence between the target image patches, which is required for the construction
of a valid multi-scale FDG-PET feature space in the next step.
The FDG-PET images were co-registered with their respective MRI images using the inter-modal linear
registration facility [17] available as part of the FSL-FLIRT program (https://fsl.fmrib.ox.ac.uk/fsl/
fslwiki/FLIRT). The quality of the co-registration was visually checked and the detected failures were
corrected by re-running FSL-FLIRT with a narrower rotation angle search range parameter to avoid getting
trapped in local minima. The estimated 12 degrees of freedom (DOF) mapping was used to transfer the
patch-wise parcellations from the MRI domain onto the FDG-PET domain. The mean FDG-PET image
intensity value in each of the mapped patches was used to calculate the patch-wise standardized uptake value
ratios (SUVRs) as, the mean intensity in a given patch divided by the mean intensity in the brainstem, chosen
as the reference ROI. This resulted in a total ofM = 17 (including the original Freesurfer parcellation) patch-
wise FDG-PET SUVR feature vectors that encoded the multi-scale regional glucose metabolism information
derived from a given target FDG-PET image.
2.6 FDG-PET DAT score computation via supervised ensemble learning
A supervised classification framework following the well established ensemble learning paradigm was used
to calculate the proposed FDG-PET DAT score from the multi-scale patch-wise SUVR feature vectors. The
main idea behind ensemble based supervised classification is to combine several individually trained classifiers
together to obtain a single, more robust classification model [18]. Accordingly, in the proposed framework,
classifiers were trained separately on each of the individual multi-scale feature vector spaces to construct
a classifier ensemble. Then, a fusion of the multiple predictions from individual classifiers in the ensemble
was performed, yielding the ensemble model estimate about the probability of the input multi-scale feature
vectors belonging to the DAT+ trajectory. This probabilistic prediction output by the ensemble classification
framework was taken to be the proposed FDG-PET DAT score.
The training samples corresponding to the DAT- and DAT+ classes needed for building the ensemble
classification model were given by the baseline sNC (N=360) and sDAT (N=238) images respectively (Table
1, footnotes 5 and 6). The proposed M multi-scale patch-wise FDG-PET SUVR feature vectors were
extracted from all the training samples. To prevent over-fitting of the ensemble model to the chosen training
sample set, the subagging approach [19] was employed to randomly generate F = 100 subsets of training
samples. The random sampling was performed using a sampling ratio of γ = 0.8 in a stratified manner
to avoid class imbalance, ensuring an equal number of samples from both the DAT- and DAT+ classes,
i.e., Ntrain = 2 × b0.8 × 238c = 380 samples in each of the F training subsets. An ensemble of M × F
probabilistic kernel [20] classifiers were individually trained on each of the M feature spaces using the F
different training subsets. The classifier training was preceded by a t-statistic based feature selection step to
identify the k = bNtrain/10c = 38 most discriminative features within the feature vector and also to address
the “curse of dimensionality” issue [13]. Each of the M × F = 1700 trained probabilistic kernel classifiers
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output a continuous scalar pi ∈ [0 1], i = {1, . . .M × F}, that denotes the probability of an input feature
vector belonging to the DAT+ class (1− pi being the DAT- class membership probability). The FDG-PET
DAT score is then simply defined as the mean of the DAT+ class probability predictions obtained from each
of the M × F classifiers.
In summary, given an unseen “test” sample containing a FDG-PET/MRI image pair, we first extract the
M multi-scale patch-wise SUVR features vectors from the images, and then reduce the dimensionality of
each of these feature vectors by retaining only the k most discriminative features that were identified during
the training phase. The pruned feature vectors are fed to the previously trained M × F classifier ensemble
to obtain M ×F probability predictions regarding the DAT+ class membership, which are then averaged to
obtain the FDG-PET DAT score corresponding to the given test sample.
3 Results
Our study dataset consisted of 2984 FDG-PET images (with corresponding structural MRI images), belong-
ing to 1294 ADNI subjects, who have undergone imaging and clinical evaluations at one or more longitudinal
time points. The images were stratified into one of the 7 study groups based on the clinical diagnosis re-
ceived at the time of image acquisition and the clinical diagnosis received previously and/or during subsequent
follow-up time points (Table 1).
In the proposed stratification scheme, we distinguish among the images that have a clinical diagnosis of
NC (sNC, uNC, pNC) at the imaging visit. Within this NC group, there are NC that will stay NC, i.e.,
stable NC (sNC, N=753 images), convert to MCI, i.e., unstable NC (uNC, N=110 images) or convert to
DAT, i.e., progressive NC (pNC, N=58 images), and hence even though all are NC, the images are treated as
distinct subgroups of the NC group given their future divergent evolution of clinical diagnosis. In a similar
fashion, we distinguish among the images with clinical diagnosis of MCI as consisting of those who will
continue to stay MCI, i.e., stable MCI (sMCI, N=881 images) throughout ADNI, or convert to AD, i.e.,
progressive MCI (pMCI, N=486 images) at a future visit. Finally, we distinguish among those images that
have an associated clinical diagnosis of DAT. Those DAT that had a previous clinical diagnosis of NC or
MCI, i.e., joined ADNI as either NC or MCI and converted to DAT during ADNI are denoted as the early
DAT group (eDAT, N=232 images) given their recent conversion, whereas those that joined ADNI with a
clinical diagnosis of DAT and hence their conversion was prior to their ADNI recruitment and remained DAT
throughout the ADNI window are designated as the stable DAT (sDAT, N=464 images). There are 110
individuals with FDG-PET images at both the pMCI and the eDAT stages, i.e., these individuals underwent
conversion from MCI to DAT during the ADNI window and this conversion was sampled with neuroimaging.
3.1 Demographic, clinical & biomarker values across groups
The 7 stratified image sets were compared for group-level differences in their associated age, mini mental
state exam (MMSE) score and CSF t-tau/Aβ1-42 measure (ratio of total tau to beta amyloid 1-42) values.
Pairwise significance testing of the group mean value differences was performed between all the groups, using
the t-test in the case of normally distributed data and the Wilcoxon ranksum test for the non-parametric data
distribution case. The p-values obtained from each of the pairwise significance tests are reported in Table
2. The statisical significance threshold was set at p<0.001. The mean age was observed to be statistically
similar across all the groups except for the uNC and pNC groups which exhibited significantly higher ages.
The mean MMSE scores were significantly higher among the sNC, uNC and pNC groups when compared to
either the sMCI and pMCI groups or the eDAT and sDAT groups. The DAT- (sNC, uNC, sMCI) groups
had significantly lower mean CSF t-tau/Aβ1-42 measures when compared to the DAT+ (pNC, pMCI, eDAT,
sDAT) groups apart from the two cases where pNC showed statistically similar CSF t-tau/Aβ1-42 measures
compared to uNC and sMCI respectively.
3.2 Automatic salient ROI selection for FPDS computation
The feature selection phase of the ensemble classification model training identified several ROIs that con-
tained strong discriminatory FDG uptake information useful for separating the DAT- and DAT+ classes.
Specifically, each of the individual 1700 classifiers in the ensemble model automatically selected a set of 38
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Table 2: The p-values corresponding to the significance of the pairwise group differences in the age, MMSE
score and CSF t-tau/Aβ1-42 measure values among the 7 stratified groups. The t-test or Wilcoxon ranksum
test was used depending on if the data followed a normal distribution or not. The cases where the group
mean values were significantly (p<0.001) different are highlighted in bold and the cases where data followed
a normal distribution are underlined.
Groups Age MMSE CSF Groups Age MMSE CSF
sNC-uNC <0.0001 0.5276 0.0046 sMCI-pNC 0.0028 <0.0001 0.0555
sNC-sMCI 0.8034 <0.0001 <0.0001 sMCI-pMCI 0.6312 <0.0001 <0.0001
sNC-pNC <0.0001 0.3760 <0.0001 sMCI-eDAT 0.0149 <0.0001 <0.0001
sNC-pMCI 0.4997 <0.0001 <0.0001 sMCI-sDAT 0.1029 <0.0001 <0.0001
sNC-eDAT 0.0211 <0.0001 <0.0001 pNC-pMCI 0.0005 <0.0001 0.0029
sNC-sDAT 0.0932 <0.0001 <0.0001 pNC-eDAT 0.0290 <0.0001 0.0055
uNC-sMCI <0.0001 <0.0001 0.5432 pNC-sDAT 0.0181 <0.0001 <0.0001
uNC-pNC 0.3340 0.6900 0.0170 pMCI-eDAT 0.0046 <0.0001 0.8320
uNC-pMCI <0.0001 <0.0001 <0.0001 pMCI-sDAT 0.0424 <0.0001 0.0047
uNC-eDAT 0.0003 <0.0001 <0.0001 eDAT-sDAT 0.2709 0.0945 0.1072
uNC-sDAT <0.0001 <0.0001 <0.0001
Table 3: Most discriminative ROIs chosen by the ensemble classification model. The ROIs are listed in
descending order of their total (left and right averaged) selection frequency. Note that only ROIs with a
non-zero selection frequency (selected at least once) are shown.
ROI Frequency (%) ROI Frequency (%)
name [Left | Right] name [Left | Right]
isthmuscingulate 100.00 | 99.65 fusiform 24.29 | 0.53
precuneus 100.00 | 83.88 medialorbitofrontal 12.76 | 10.29
inferiortemporal 99.82 | 83.35 superiorfrontal 14.29 | 5.94
posteriorcingulate 96.12 | 85.06 superiortemporal 11.94 | 5.24
middletemporal 99.35 | 80.71 lateralorbitofrontal 12.18 | 2.24
inferiorparietal 99.18 | 64.94 superiorparietal 11.41 | 3.00
supramarginal 67.41 | 26.06 parsopercularis 9.88 | 1.06
entorhinal 57.94 | 32.53 temporalpole 9.35 | 0.18
hippocampus 47.82 | 32.00 rostralanteriorcingulate 5.18 | 0.00
bankssts 27.76 | 15.82 frontalpole 0.82 | 0.82
rostralmiddlefrontal 24.94 | 17.18 caudate 0.71 | 0.00
amygdala 22.18 | 17.29 parstriangularis 0.35 | 0.00
parahippocampal 28.00 | 10.06 parsorbitalis 0.18 | 0.00
caudalmiddlefrontal 22.76 | 13.18
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most discriminative ROIs from which the multi-scale patch-wise FDG-PET SUVR features were taken and
used to compute the FPDS. In Table 3, selection frequencies of the ROIs chosen by the classifier ensemble are
listed. The selection frequency of a ROI is defined as the fraction of the classifiers in the ensemble that chose
the particular ROI. Interestingly, ROIs from the left hemisphere exhibited much higher selection frequencies
compared to the corresponding right hemisphere ROIs. Further, the cortical ROIs had far greater selection
frequencies than the subcortical ROIs. In particular, the isthmus and posterior parts of the cingulate gyrus,
the precuneus and the inferior and middle temporal gyri had very high (>90%) total (left and right averaged)
selection frequencies.
3.3 FPDS distribution among training (sNC and sDAT) groups
In Figure 1, the distribution of FPDS values among the baseline and follow-up images from the sNC and
sDAT groups are shown. As the baseline images were used for training the ensemble model, the FPDS values
for the baseline images were determined via the out-of-bag prediction approach to avoid biased estimates. In
this approach, the FPDS for a given baseline image was computed by only fusing predictions from classifiers
in the ensemble that did not have the given baseline image as part of their subagging training subset. The
follow-up images were not involved in the ensemble model training, so they were treated as unseen test
samples and their FPDS values were computed using the standard approach of fusing predictions from all
the classifiers in the ensemble. It can be seen from Figure 1 that the FPDS distributions of the sNC and
sDAT groups are very well separated with an excellent (>0.95) area under the curve (AUC) of the receiver
operating characteristic (ROC) in both the baseline and follow-up image cases. Moreover, high specificities
and sensitivities (∼ 0.90 balanced accuracies) were achieved when using a FPDS threshold of 0.5 to classify
the baseline and follow-up images as belonging to either the DAT- or the DAT+ trajectory.
3.4 FPDS distribution among the validation image groups
Imaging data from the uNC and sMCI groups that belong to the DAT- trajectory, along with images from
the pNC, pMCI and eDAT groups that are on the DAT+ trajectory constituted the independent validation
set used for evaluating the proposed ensemble model framework for FPDS computation. In Figure 2, FPDS
distributions across these independent validation image groups are shown. In general, the mean FPDS values
among the DAT- trajectory groups (<0.4) were much lower compared to the FPDS group means across the
DAT+ trajectory groups (>0.6), except for the pNC group which had a mean FPDS value of 0.35 which
was similar to that of the DAT- groups. It should however also be noted that the pNC group contained far
fewer images (N=58) in comparison to the other groups. Overall, there was a good degree of separation
between the DAT- and DAT+ FPDS distributions resulting in an AUC of 0.78. Further, this separability
translated into a balanced accuracy of 0.70 when the images were classified into either the DAT- or the
DAT+ trajectory using a 0.5 FPDS threshold.
3.5 FPDS trend across age ranges in validation image groups
The mean FPDS values and classification accuracies (based on 0.5 FPDS threshold) obtained from the vali-
dation image subsets taken across different age ranges within the uNC and sMCI groups (DAT- trajectory),
and the pNC, pMCI and eDAT groups (DAT+ trajectory) are presented in Figure 3. The FPDS means in
the sMCI group gradually increased from less than 0.2 in the younger age ranges (55 - 70 years) to greater
than 0.5 among the older age ranges (85 - 95 years). This wide and gradual variation of FPDS values mani-
fested as a steady decrease in the accuracy of identifying the sMCI images as DAT- from above 0.85 in the
younger age ranges (55 - 70 years) to below 0.5 in the older age ranges (85 - 95 years). The eDAT group
exhibited uniformly high FPDS mean values across all the age ranges lying in a short interval of 0.74 - 0.9.
Consequently, a majority of the eDAT images were correctly classified as DAT+, leading to a high overall
accuracy of 0.89. In contrast to the sMCI and eDAT groups, no consistent age-related patterns of FPDS
mean values and classification accuracies were observed among the uNC, pNC and pMCI groups. The pMCI
group displayed relatively high FPDS mean values (>0.67) in three disjoint age ranges 55 - 60, 70 - 75 and
85 - 90 years, and accordingly the classification accuracies of 0.85, 0.71 and 0.81 respectively observed in
these age ranges, were considerably higher than the overall pMCI group average of 0.68. Surprisingly, the
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Figure 1: FPDS distribution among the sNC and sDAT images and classification performance obtained in
assigning images to either the DAT- or DAT+ trajectory using a 0.5 FPDS threshold. The top row presents
the out-of-bag predictions on the baseline images, which were used for training the ensemble model. The
bottom row shows ensemble model predictions on the follow-up subgroup. The follow-up images were not
part of training and hence were considered as unseen test samples for the purpose of FPDS computation.
The (number of images : mean FPDS) is shown for each subgroup. Balanced accuracy is the mean of the
sensitivity and specificity measures.
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Figure 2: The FPDS distribution among validation image groups and the classification performance obtained
in determining dementia trajectories (DAT- or DAT+) for these images using a 0.5 FPDS threshold. The
FPDS histograms corresponding to the groups on the DAT- (uNC, sMCI) and the DAT+ (pNC, pMCI,
eDAT) trajectories are stacked together respectively. The (number of images : mean FPDS) is shown for
each group. Balanced accuracy is mean of sensitivity and specificity.
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pNC and uNC groups were found to have a similar FPDS mean in the 70 - 75 years range, and further in
the following 75 - 80 and 85 - 90 years ranges the pNC group had lower FPDS means relative to the uNC
group. This lead to mis-labeling of most pNC images as DAT-, yielding a very poor overall classification
accuracy of 0.28.
3.6 FPDS versus time to conversion in progressive image groups
In Figure 4, the mean FPDS values and classification accuracies (based on 0.5 FPDS threshold) computed
from image subsets taken across different ranges of time to conversion within the the pNC and pMCI groups
are shown. The time to conversion is defined as the number of years from the image scan date to the earliest
future timepoint at which the subject associated with the image was given a clinical diagnosis of DAT. The
pMCI group exhibited relatively high mean FPDS values (0.64 - 0.71) among the 0 - 3 years to conversion
range. But, in the later time to conversion ranges, especially beyond the 4 years to conversion range, a
considerable decrease (0.26 - 0.46) in the FPDS means was observed. Therefore, for the pMCI group, good
classification accuracies (0.7 - 0.78) were only observed in the 0 - 3 years to conversion range, past which the
pMCI images were frequently misclassified as DAT-, reducing the overall accuracy to 0.68. The pNC group
showed low FPDS mean values (0.17 - 0.52) across all the time to conversion ranges, leading to incorrect
labeling of more than 72% of the pNC images as DAT- (0.28 overall classification accuracy).
3.7 Correlation between FPDS and CSF t-tau/Aβ1-42
To investigate the causal association of FPDS with established ADP measures, Pearson correlation analysis
was performed between the CSF t-tau/Aβ1-42 and FPDS values. The correlation results obtained across the
training (Figure 5) and independent validation (Figure 6) image groups are reported. In the case of training
image groups, correlation analysis was performed using the combined set of baseline and follow-up images
in each of the sNC and sDAT groups respectively. The spread of t-tau/Aβ1-42 values in the sNC group (0.1
- 1.54) was relatively narrow as compared to sDAT group (0.15 - 3.6). Both the sNC and sDAT groups
showed a weak yet positive correlation between the t-tau/Aβ1-42 and FPDS, with the sDAT group showing a
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Figure 3: Age-based analysis of FPDS score: heat map plots showcasing the trend of mean FPDS (top)
and classification accuracy (bottom) obtained across different age ranges within each of the validation image
groups. The classification accuracies were calculated using a 0.5 FPDS threshold. The number of images in
a (image group,age range) is printed on the corresponding heat map cell, while the total number of images
within a group is shown in parentheses under each column of the heat maps. The overall mean FPDS and
classification accuracy within a group are given above respective heat map columns.
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Figure 4: Heat maps showing variation of mean FPDS (left) and classification accuracy (right) across different
time to conversion ranges in the progressive image groups (pNC and pMCI). The time to conversion indicates
the number of years from the image scan date to the first clinical diagnosis of DAT for the subject associated
with the image. A FPDS threshold of 0.5 was used to calculate the classification accuracies. The number of
images in a (image group,time to conversion range) is printed on the corresponding heat map cell, while the
total number of images within a group is shown in parentheses under each column of the heat maps. The
overall mean FPDS and classification accuracy within a group are given above respective heat map columns.
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Figure 5: Pearson correlation between CSF t-tau/Aβ1-42 and FPDS across the sNC and sDAT images
(baseline and follow-up combined). The CSF t-tau/Aβ1-42 measures were only available for a subset of
images and their numbers are shown in parentheses. The statistical significance threshold for correlation
coefficient (r) was set at p<0.05.
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relatively stronger correlation coefficient (r=0.13) that was also statistically significant (p=0.0489). Among
the validation image groups, the t-tau/Aβ1-42 values of the NC groups (uNC and pNC) had a relatively
narrow range (0.11 - 1.47) compared to the other DAT- (sMCI) and DAT+ (pMCI and eDAT) groups.
In general, the FPDS was weakly, but positively correlated with t-tau/Aβ1-42. The correlation coefficient
ranged between 0.13 - 0.31 among the various groups considered. However, correlation coefficients exhibited
by DAT- groups (uNC and sMCI) were found to be statistically significant (p=0.0380 and p<0.0001), whereas
the DAT+ (pNC, pMCI and eDAT) groups only exhibited a trend of positive correlations with r-values in
the 0.13 - 0.24 interval.
4 Discussion
In this paper we report the development and validation of a novel FDG-PET DAT score (FPDS). We
computed the FPDS using a multi-scale supervised ensemble learning approach on FDG-PET images. The
FPDS is a single scalar value between 0 and 1. It indicates the probability of the brain metabolism profile
captured in a subject’s FDG-PET image to be belonging to the DAT+ trajectory. The FPDS was developed
in an ensemble machine-learning paradigm trained on FDG-PET images belonging to sNC and sDAT subjects
from the ADNI database. FPDS as a DAT biomarker was then comprehensively validated on a large
number of ADNI FDG-PET images (N=2984) across the sNC, uNC, sMCI, pNC, pMCI, eDAT and sDAT
stratification.
4.1 Real-world stratification scheme
The proposed stratification of imaging data into the 7 groups (Table 1) provided a clinically relevant perspec-
tive for the development of the FPDS framework. Particularly, the stratification scheme helped establish a
clear delineation between images taken from subjects on the DAT- and DAT+ trajectories, and thus formu-
lating DAT biomarker discovery as a supervised machine learning problem of building a classification model
that can predict the probability of an image belonging to either the DAT- or DAT+ class. Most previous
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Figure 6: Pearson correlation between the CSF t-tau/Aβ1-42 and FPDS values across the independent
validation image groups. Only a subset of images in each group had CSF t-tau/Aβ1-42 measures available.
The number of images with t-tau/Aβ1-42 values are given in parentheses. Correlation coefficient (r) was
considered significant at p<0.05.
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studies on imaging biomarkers were limited to stratifying images based on the NC, MCI and DAT diagnostic
labels assigned at the time of image acquisition [9]. However, in recent years there has been interest in
developing early stage DAT biomarkers adopting a sMCI/pMCI stratification of images associated with a
clinical diagnosis of MCI [21]. Our novel approach extends this MCI image stratification idea to the entire
DAT spectrum by also stratifying the NC and DAT images into the sNC/uNC/pNC and eDAT/sDAT groups
respectively. This enabled the validation of the FPDS in a realistic experimental setting that is quite close to
a practical clinical setup, where images from the uNC, sMCI, pNC, pMCI and eDAT groups were completely
blinded from the trained ensemble classification model. We put forth our stratification approach as an ideal
benchmark to evaluate future DAT biomarker methods.
4.2 Characteristics of the stratified groups
The training and validation image sets used in our analysis were found to be unbiased with respect to the
associated relevant non-imaging phenotypic information, justifying the ignoring of non-imaging covariates
in the proposed supervised learning framework. The age, MMSE and CSF t-tau/Aβ1-42 values observed
across the stratified groups did not reveal any anomalous group difference patterns (Table 1 and Table 2)
that could potentially confound the proposed FDG-PET imaging based analysis. Most importantly, the
sNC and sDAT groups used for training the FPDS model had similar mean ages, and further as expected
the sNC group had a significantly higher MMSE but a significantly lower t-tau/Aβ1-42 compared to the
sDAT group. Moreover, mean ages among the sMCI, pMCI and eDAT groups in the validation image set
were also comparable to the training groups. The other two validation groups namely uNC and pNC had
slightly, yet statistically significantly higher mean ages (∼ 3 years older) than the training groups. However,
this significant group difference might just be reflective of a sampling bias given that the uNC (N=110)
and pNC (N=58) groups have considerably fewer images compared to the training groups, sNC (N=753)
and sDAT (N=464). The group differences in MMSE and t-tau/Aβ1-42 values between the validation and
training groups followed known patterns, where the DAT- groups (uNC and sMCI) showed significantly
higher mean MMSE but significantly lower mean t-tau/Aβ1-42 when compared to the sDAT group, whereas
the DAT+ groups (pNC, pMCI and eDAT) had significantly lower mean MMSE but significantly higher
mean t-tau/Aβ1-42 in comparison to the sNC group.
4.3 FPDS computation model characteristics
Two aspects of the trained ensemble classification model warrant further discussion, viz., the ROIs chosen by
the model for FPDS computation (Table 3), and the model’s predictive performance on the sNC and sDAT
groups (Figure 1).
The ROIs selected by the ensemble model included parieto-temporal regions along with precuneus and
cingulate gyrus. Recent studies have demonstrated the hypometabolism of parieto-temporal regions including
precuneus and posterior cingluate as earliest evidences for MCI progression to DAT [22, 23]. Further, left
hemisphere regions were chosen more often compared to their corresponding contralateral regions. Similar,
preferential left sided hypometabolism was reported during early stages of DAT [24]. Hence, the ROIs
chosen by the ensemble model for FPDS computation are consistent with established spatial hypometabolism
patterns in DAT.
The ensemble model’s FPDS predictions on the sNC and sDAT images were consistent with the fact
that these images belong to individuals who are at the extremities of the DAT spectrum, i.e., the FPDS
distributions of sNC and sDAT were skewed and only had a small overlap with AUCs of 0.95 and 0.98 for
the baseline and follow-up subgroups respectively. Interestingly, among the sNC images with FPDS>0.5
(misclassified as DAT+), the mean t-tau/Aβ1-42 was found to be slightly higher (0.42 vs 0.36, p=0.2463)
than the sNC images with FPDS<=0.5 (correctly identified as DAT-). Whereas, in sDAT images with
FPDS<=0.5 (misclassified as DAT-), the mean t-tau/Aβ1-42 was statistically significantly lower (0.84 vs
1.06, p=0.0073) when compared to sDAT images with FPDS>0.5 (accurately labeled as DAT+). These
observations agree with the positive correlations found between the t-tau/Aβ1-42 and FPDS values among
the sNC and sDAT groups respectively (Figure 5). The occurrence of DAT like metabolism patterns (higher
FPDS) among the misclassified sNC might be owing to their increased t-tau/Aβ1-42 values and in a similar
manner the shift away from DAT metabolism patterns (lower FPDS) among the misclassified sDAT could
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be attributed to their relatively lower t-tau/Aβ1-42 values.
The predictive performance of the ensemble model is on par with (or better than) the sNC vs sDAT
classification results published in latest FDG-PET imaging based studies, which showed AUCs ranging from
0.93 on a cohort of 52 sNC and 51 sDAT images [25] to 0.97 on a 117 sNC and 113 sDAT cohort [26]. These
studies evaluated their classification models using a 10-fold cross-validation scheme, which is known [27] to
produce generalization error estimates (measure of predictive performance on unseen data) similar to that
of the out-of-bag prediction scheme, that was used for evaluation of the ensemble model on baseline sNC
and sDAT images. However, arguably the ensemble model’s performance on the follow-up images gives a
much better estimate of the generalization error, as the follow-up images were completely hidden during the
ensemble model training process and hence can be considered as unseen data, despite their implicit relation
to the corresponding baseline images. It’s also important to highlight the relatively large sample size of the
follow-up image set (393 sNC and 226 sDAT images) in comparison to the cohorts used in previous FDG-
PET studies [25, 26, 6]. This further underscores the confidence in the reported predictive performance of
the ensemble model on sNC and sDAT groups.
4.4 Comprehensive evaluation of the FPDS computation model
The ensemble classification model’s predictive performance evaluated on a large independent validation set
of images (N=1767), taken from individuals at different stages of AD spectrum, provided a rigorous and
a realistic way to assess the potential of using FPDS for DAT diagnosis (Figure 2). The ensemble model
achieved an AUC of 0.78 in discriminating the DAT- (uNC and sMCI) and the DAT+ (pNC, pMCI and
eDAT) groups, strongly advocating the consideration of FPDS as a DAT biomarker. A more detailed
analysis of the FPDS predictions across the DAT- and DAT+ groups revealed a non-trivial association
between the t-tau/Aβ1-42 and FPDS values. The DAT- images with FPDS>0.5 (misclassified as DAT+) had
statistically significantly higher mean t-tau/Aβ1-42 (0.71 vs 0.49, p<0.0001) compared to the DAT- images
with FPDS<=0.5 (correctly labeled as DAT-). While, the mean t-tau/Aβ1-42 among the DAT+ images with
FPDS<=0.5 (misclassified as DAT-) was found to be significantly lower (0.74 vs 0.94, p=0.0015) compared
to the DAT+ images with FPDS>0.5 (correctly labeled as DAT+). In light of these findings, along with
the positive correlations observed between t-tau/Aβ1-42 and FPDS within each of the DAT- and DAT+
groups (Figure 6), it can be speculated that the relatively higher t-tau/Aβ1-42 values might be triggering the
presence of DAT like metabolism patterns (higher FPDS) in misclassified DAT-. Similarly, the comparatively
lower t-tau/Aβ1-42 values could be the underlying cause behind the lack of DAT like metabolism patterns
(lower FPDS) among the misclassified DAT+.
The predicted FPDS values for the sMCI images were observed to increase with age (Figure 3), i.e.,
images corresponding to older subjects tended to have higher FPDS values compared to images taken from
younger subjects. In particular, when comparing the two subgroups of sMCI images whose age ranges were
above and below the average sMCI age of ∼ 75 years (Table 1) respectively, the mean FPDS for the images
in the older subgroup was found to be significantly greater than the mean FPDS among the images from the
younger subgroup (0.45 vs 0.22, p<0.0001). Further, as could be expected based on the statistically significant
positive correlation observed between FPDS and t-tau/Aβ1-42 in sMCI (r = 0.2526 with p<0.0001, Figure 6),
the older subgroup also showed a significantly higher mean t-tau/Aβ1-42 compared to the younger subgroup
(0.61 vs 0.51, p<0.0001). Apart from the sMCI group, none of the other uNC, pNC, pMCI and eDAT groups
displayed any apparent age specific FPDS patterns (Figure 3). Nevertheless, among these groups a trend of
positive correlations between t-tau/Aβ1-42 and FPDS was observed (Figure 6). This suggests a possible age
independent causal relationship between t-tau/Aβ1-42 and the occurrence of DAT like metabolism patterns.
In the pMCI group, the predicted FPDS values were found to decrease with longer time to conversion
(Figure 4). Notably, the mean FPDS for the subgroup of images that were within 4 years to conversion
was significantly higher than that of the image subgroup whose conversion times exceeded 4 years (0.67
vs 0.43, p<0.0001). Moreover, in concordance with the positive correlation observed between t-tau/Aβ1-42
and FPDS among the pMCI (r = 0.1312 with p<0.0609, Figure 6), the mean t-tau/Aβ1-42 for the within
4 years to conversion subgroup was also significantly higher compared to the subgroup with longer than 4
year conversion times (0.91 vs 0.66, p=0.0229). Based on these findings it is conceivable that, from around 4
years prior to a clinical diagnosis of DAT there might be a noticeable increase in the t-tau/Aβ1-42 causing a
prevalence of DAT like metabolism patterns among the pMCI. While beyond the 4 year conversion window,
16
Table 4: Comparison of sMCI vs pMCI classification performance obtained using FPDS with the state-of-
the-art FDG-PET based methods.
sMCI:pMCI Time to Evaluation
Study [images] conversion scheme AUC
[29] 56:43 0-2 years 10-fold cross-validation 0.774
[30] 56:43 0-2 years 10-fold cross-validation 0.734
[31] 56:43 0-2 years 10-fold cross-validation 0.741
FPDS 881:254 0-2 years independent validation 0.806
[28] 96:47 0-3 years independent validation 0.767
[32] 181:60 0-3 years independent validation 0.746
[33] 65:64 0-3 years leave-one-out cross-validation 0.802
[36] 108:126 0-3 years prediction on training set 0.736
FPDS 881:362 0-3 years independent validation 0.796
[34] 27:95 0-5 years 21-fold cross-validation 0.911
[35] 19:49 0-5 years independent validation 0.712
FPDS 881:442 0-5 years independent validation 0.772
it can be expected that there would be a considerable reduction in the appearance of DAT like metabolism
patterns in pMCI. In fact, metabolic disruptions in an earlier NC stage of pMCI were found to be virtually
undetectable as evidenced by the significantly lower mean FPDS of the pNC group compared to the pMCI
(0.35 vs 0.63, p<0.0001) and also indicated by the extremely low classification accuracy (0.28, Figure 4)
achieved on pNC images.
4.5 MCI conversion prediction - comparison with state-of-the-art
Several FDG-PET image analysis methods have previously been considered for addressing the task of pre-
dicting MCI to DAT conversion [28, 29, 30, 31, 32, 33, 34, 35, 36]. In these methods, the main idea is to
train a binary classification model for separating the MCI into two groups, the sMCI which remain stable
and the pMCI that convert to DAT in the future. Aside from the standard approach of using images from
the sMCI and pMCI groups as training data [33, 34, 29], some of the methods have augmented the training
process with information derived from the sNC and sDAT images as well [36, 32, 30, 31]. Further, akin
to the proposed approach for training the FPDS computation model, there were a few methods that solely
employed the sNC and sDAT images during the training phase [28, 35].
In Table 4, the sMCI vs pMCI classification results reported in the aforementioned works are summarized.
Table 4 also shows the AUC achieved when using the FPDS to discriminate between the sMCI and the pMCI
that are within 2, 3 and 5 years to conversion respectively. The proposed FPDS based approach outperformed
almost all of the state-of-the-art methods achieving an AUC of more than 0.77 in each of the three time
to conversion cases. Only [33] and [34] reported higher AUCs than the proposed approach. However,
these two methods reported the cross-validated AUC, whereas a more challenging independent validation
experiment was used to evaluate the performance of the FPDS approach. Moreover, in [33] and [34], the
classification model parameter tuning was done using the testing subsets of the cross-validation splits which
leads to inflated estimates of the classification performance. In fact to avoid such an optimistic performance
evaluation, the other methods reporting cross-validated AUCs [29, 30, 31] used “nested” cross-validation,
where the classification model parameters were tuned on the training subsets of the cross-validation splits
rather than the testing subsets. Last, it should be highlighted that the better performance of the FPDS
approach was demonstrated on a considerably larger sample size (>5x more images) compared to the other
methods.
4.6 Limitations and future directions
The results reported in this paper are understandably limited by the ADNI data characteristics. In gen-
eral, the final (at time of death) clinical diagnosis for ADNI subjects is not known, this is because either
the subjects are surviving or they were not followed-up around their demise. Consequently, it is possible
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that some subjects currently determined to be on the DAT- trajectory, i.e., with images belonging to the
sNC/uNC/sMCI groups, might receive a clinical diagnosis of DAT in the future. While this is a limitation in
our current results, in case the final diagnosis for such subjects becomes available, it would be interesting to
review if the ensemble model had actually correctly predicted the sNC/uNC/sMCI images of these subjects
as belonging to the DAT+ trajectory (FPDS>0.5). Another limitation of the reported results, as mentioned
before, is that the correlation analysis between the FPDS and t-tau/Aβ1-42 values was reported only on a
subset of the images owing to partial availability of CSF measures in the ADNI database. In spite of these
ADNI data related limitations, it is important to note that both the novel stratification scheme and the en-
semble classification framework proposed in our work have a more general applicability and are not specific
to the ADNI cohort used in this study. In fact, as part of future work we plan to extend our methodology
to incorporate multimodal imaging data and validate it on other relevant AD neuroimaging databases.
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